Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Branch Retinal Vein Occlusion
Intervention: Bevacizumab (Drug); Triamcinolone Acetonide (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Shahid Beheshti Medical University
Summary
This randomized clinical trial is conducted to evaluate the effect of three intravitreal
injections of bevasizumab versus two intravitreal injections of triamcinolone in acute
retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The
follow-up time is 6 months.
Clinical Details
Official title: Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: Visual acuity
Secondary outcome: central macular thickness
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Recent onset (less than 3 months) BRVO
Exclusion Criteria:
- Any previous intervention
Locations and Contacts
Imam Hossein medical center, Tehran, Iran, Islamic Republic of; Recruiting Alireza Ramezani, Assistant professor, Email: arramezani@gmail.com Alireza Ramezani, Assistant professor, Principal Investigator
Additional Information
Starting date: January 2010
Last updated: January 6, 2010
|